Imwe Mubishyushye Byera 4-Bromo-1-Methylpyrazole CAS 15803-02-8 hamwe nigiciro cyiza

Hamwe nubuyobozi bwacu budasanzwe, ubushobozi bukomeye bwa tekiniki hamwe nuburyo bukomeye bwo kugenzura ubuziranenge, dukomeje guha abakiriya bacu ibiciro byizewe byo mu rwego rwo hejuru, byumvikana byo kugurisha hamwe nabatanga ibicuruzwa byiza.Dufite intego yo kuba mubafatanyabikorwa bawe bashinzwe kandi tukanezezwa na Umwe Mubishyushye Bwera Bwinshi 4-Bromo-1-Methylpyrazole CAS 15803-02-8 hamwe nigiciro cyiza, Dutegereje byimazeyo gukorana nabaguzi kwisi yose .Turatekereza ko tuzaguhaza.Twishimiye kandi abaguzi gusura ishyirahamwe ryacu no kugura ibicuruzwa byacu.
Hamwe nubuyobozi bwacu budasanzwe, ubushobozi bukomeye bwa tekiniki hamwe nuburyo bukomeye bwo kugenzura ubuziranenge, dukomeje guha abakiriya bacu ibiciro byizewe byo mu rwego rwo hejuru, byumvikana byo kugurisha hamwe nabatanga ibicuruzwa byiza.Dufite intego yo kuba mubafatanyabikorwa bawe bashinzwe kandi tukabona umunezero waweUbushinwa CAS 15803-02-8 na 15803-02-8, Twubatse umubano ukomeye kandi muremure wubufatanye ninshi mubigo byinshi muri ubu bucuruzi mumahanga.Serivise ako kanya ninzobere nyuma yo kugurisha itangwa nitsinda ryacu ryabajyanama ryishimiye abaguzi bacu.Ibisobanuro birambuye hamwe nibipimo biva mubicuruzwa birashoboka koherezwa kubwawe byemewe.Ingero z'ubuntu zirashobora gutangwa kandi isosiyete ikagenzura isosiyete yacu.n Porutugali kugirango imishyikirano ihora ikaze.Twizere kubona anketi wandike kandi wubake ubufatanye bwigihe kirekire.

1-Bromo-2-mikorerexy-3-nitro-benzene ikoreshwa nkigihe cya Eltrombopag.
Eltrombopag, yakozwe na GlaxoSmithKline (GSK) mu Bwongereza nyuma iza gukorana na Novartis mu Busuwisi, ni yo ya mbere kandi yemewe ya molekile ntoya itari peptide TPO yakira agonist ku isi.Eltrombopag yemejwe na FDA yo muri Amerika muri 2008 kugirango ivure idiopathic trombocytopenic purpura (ITP), naho muri 2014 yo kuvura anemia ikabije (AA).Ninumuti wambere wemejwe na FDA yo muri Amerika kuvura AA mumyaka 30 ishize.
Ukuboza2012, FDA yo muri Amerika yemeye Eltrombopag kuvura trombocytopenia ku barwayi barwaye hepatite C idakira (CHC), ku buryo abarwayi ba hepatite C bafite uburwayi buke buterwa na platine nkeya bashobora gutangira kandi bagakomeza kuvura bisanzwe bishingiye ku ndwara z’umwijima.Ku ya 3 Gashyantare 2014, GlaxoSmithKline yatangaje ko FDA yatanze impamyabumenyi y’ubuvuzi ya Eltrombopag yo kuvura indwara ya hémopenia ku barwayi bafite imiti ikaze y’imiti idakira (SAA) ititabira byimazeyo ubudahangarwa bw'umubiri.Ku ya 24 Kanama 2015, FDA yo muri Amerika yemeje Eltrombopag kuvura trombocytopenia ku bantu bakuru ndetse n’abana bafite imyaka 1 n’imyaka irenga hamwe na immunite trombocytopenia idakira (ITP) badafite ibisubizo bidahagije kuri corticosteroide, immunoglobuline cyangwa splenectomy.Ku ya 4 Mutarama 2018, Eltrombopag yemerewe gushyirwa ku rutonde mu Bushinwa kugira ngo ivurwe mbere na mbere na trombocytopenia (ITP).

Hamwe nubuyobozi bwacu budasanzwe, ubushobozi bukomeye bwa tekiniki hamwe nuburyo bukomeye bwo kugenzura ubuziranenge, dukomeje guha abakiriya bacu ibiciro byizewe byo mu rwego rwo hejuru, byumvikana byo kugurisha hamwe nabatanga ibicuruzwa byiza.Dufite intego yo kuba mubafatanyabikorwa bawe bashinzwe kandi tukanezezwa na Umwe Mubishyushye Bwera Bwinshi 4-Bromo-1-Methylpyrazole CAS 15803-02-8 hamwe nigiciro cyiza, Dutegereje byimazeyo gukorana nabaguzi kwisi yose .Turatekereza ko tuzaguhaza.Twishimiye kandi abaguzi gusura ishyirahamwe ryacu no kugura ibicuruzwa byacu.
Kimwe mu Bishyushye kuriUbushinwa CAS 15803-02-8 na 15803-02-8, Twubatse umubano ukomeye kandi muremure wubufatanye ninshi mubigo byinshi muri ubu bucuruzi mumahanga.Serivise ako kanya ninzobere nyuma yo kugurisha itangwa nitsinda ryacu ryabajyanama ryishimiye abaguzi bacu.Ibisobanuro birambuye hamwe nibipimo biva mubicuruzwa birashoboka koherezwa kubwawe byemewe.Ingero z'ubuntu zirashobora gutangwa kandi isosiyete ikagenzura isosiyete yacu.n Porutugali kugirango imishyikirano ihora ikaze.Twizere kubona anketi wandike kandi wubake ubufatanye bwigihe kirekire.